Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Vascular disorders – page 51

  • 838 clinical trials
  • 353 recruiting
  • 378 conditions
  • 28 countries

Conditions in this area

378 conditions with trials, the busiest first

Ischaemic stroke52Migraine48Systemic scleroderma39Pulmonary arterial hypertension38Coronary artery disease37Arteriosclerosis32Acute myocardial infarction30Hypertension27Pulmonary hypertension23Acute coronary syndrome21Giant cell arteritis18Peripheral arterial occlusive disease17Septic shock17Cardiovascular disorder16Paroxysmal nocturnal haemoglobinuria16Subarachnoid haemorrhage16Acute respiratory distress syndrome15Atrial fibrillation15Cerebrovascular accident14Pulmonary embolism14Anti-neutrophil cytoplasmic antibody positive vasculitis13Diabetic foot13Embolism13Myocardial infarction13+354

Clinical trials in Vascular disorders

838 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

838 clinical trials

Acute myocardial infarction+1

Not recruiting

Study on the Effects of Warfarin, Lysine Aspirin, and Clopidogrel in Patients with Myocardial Infarction and Non-Obstructive Coronary Arteries (MINOCA)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Hypertension

Not recruiting

Study on the Effectiveness and Safety of Nebivolol for Treating High Blood Pressure in Adolescents

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Nebivolol Hydrochloride
  • Sponsor:Medical University Of Warsaw

Subarachnoid haemorrhage+1

Not recruiting

Study on Urea for Treating Low Sodium Levels in Patients with Brain Hemorrhage

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Urea
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Atrial fibrillation+1

Not recruiting

Study on Edoxaban for Patients with Atrial Fibrillation and Previous Brain Bleeding

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Edoxaban
  • Sponsor:Hamilton Health Sciences Corporation

Peripheral arterial occlusive disease

Not recruiting

Study on Genotype-Guided Treatment with Carbasalate Calcium, Telmisartan, and Rivaroxaban for Patients with Peripheral Arterial Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carbasalate Calcium
  • Sponsor:Stichting Radboud University Medical Center

Cryoglobulinaemia

Not recruiting

Study of Isatuximab for Patients with Type I Cryoglobulinemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Isatuximab
  • Sponsor:Assistance Publique Hopitaux De Paris

Septic shock

Not recruiting

Study on Ivabradine for Heart Rate Control and Survival in Adults with Septic Shock

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ivabradine Hydrochloride
  • Sponsor:Assistance Publique Hopitaux De Paris

Pulmonary hypertension

Not recruiting

Study of TX000045 for Pulmonary Hypertension in Heart Failure Patients with Preserved Ejection Fraction

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:TX000045
  • Sponsor:Tectonic Therapeutic Inc.

Cushing's syndrome

Not recruiting

Study on the Long-Term Safety of Relacorilant for Patients with Cushing Syndrome

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Corcept Therapeutics Inc.

Pulmonary hypertension

Not recruiting

Study on the Effects of Mosliciguat for Patients with Pulmonary Hypertension Linked to Interstitial Lung Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
  • Sponsor:Pulmovant Inc.

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Long-term safety and effectiveness study of pozelimab and cemdisiran combination treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on the Safety and Effectiveness of Pozelimab and Cemdisiran for Adults with Paroxysmal Nocturnal Hemoglobinuria Not Recently Treated with Complement Inhibitors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Acetylsalicylic Acid59 clinical trialsSodium Chloride55 clinical trialsClopidogrel33 clinical trialsApixaban28 clinical trialsTicagrelor28 clinical trialsRivaroxaban21 clinical trialsAtorvastatin17 clinical trialsPrasugrel17 clinical trialsRituximab16 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.